{"doi":"10.3233/jad-221209","title":"White Matter Hyperintensity Volume and Amyloid-PET Synergistically Impact Memory Independent of Tau-PET in Older Adults Without Dementia","abstract":"BACKGROUND: Alzheimer's disease (AD) and cerebrovascular disease are common, co-existing pathologies in older adults. Whether the effects of cerebrovascular disease and AD biomarkers on cognition are additive or synergistic remains unclear. OBJECTIVE: To examine whether white matter hyperintensity (WMH) volume moderates the independent association between each AD biomarker and cognition. METHODS: In 586 older adults without dementia, linear regressions tested the interaction between amyloid-β (Aβ) positron emission tomography (PET) and WMH volume on cognition, independent of tau-PET. We also tested the interaction between tau-PET and WMH volume on cognition, independent of Aβ-PET. RESULTS: Adjusting for tau-PET, the quadratic effect of WMH interacted with Aβ-PET to impact memory. There was no interaction between either the linear or quadratic effect of WMH and Aβ-PET on executive function. There was no interaction between WMH volume and tau-PET on either cognitive measure. CONCLUSION: Results suggest that cerebrovascular lesions act synergistically with Aβ to affect memory, independent of tau, highlighting the importance of incorporating vascular pathology into biomarker assessment of AD.","journal":"Journal of Alzheimer s Disease","year":2023,"id":352677,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.967,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":243718,"name":"for the Alzheimer’s Disease Neuroimaging Initiative","orcid":null,"position":1,"is_corresponding":false},{"id":316753,"name":"Kelsey R. Thomas","orcid":"0000-0003-4277-8876","position":2,"is_corresponding":false},{"id":316752,"name":"Alexandra J. Weigand","orcid":"0000-0002-7931-1383","position":3,"is_corresponding":false},{"id":336798,"name":"Emily C. Edmonds","orcid":"0000-0002-5130-0500","position":4,"is_corresponding":false},{"id":381682,"name":"Alexandra L. Clark","orcid":"0000-0002-7437-5409","position":5,"is_corresponding":false},{"id":900263,"name":"Kayla S. Walker","orcid":null,"position":6,"is_corresponding":false},{"id":905843,"name":"Einat K. Brenner","orcid":"0000-0002-0172-8277","position":7,"is_corresponding":false},{"id":283896,"name":"Daniel A. Nation","orcid":"0000-0002-9123-0658","position":8,"is_corresponding":false},{"id":277081,"name":"Pauline Maillard","orcid":"0000-0003-3516-6345","position":9,"is_corresponding":false},{"id":316758,"name":"Mark W. Bondi","orcid":"0000-0002-1742-3451","position":10,"is_corresponding":false},{"id":316754,"name":"Katherine J. Bangen","orcid":"0000-0002-1363-3179","position":11,"is_corresponding":false},{"id":300910,"name":"Lauren Edwards","orcid":"0000-0002-8434-9669","position":0,"is_corresponding":true}],"reference_count":59,"raw_metadata":null,"created_at":"2026-07-19T01:12:54.209378Z","pmid":"37302031","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}